These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 39263925

  • 1. Chromosome 1q21 Aberrations Are Poor Prognostic Factors for Newly Diagnosed Multiple Myeloma Patients.
    Wang T, Geng C, Yang G, Zhou H, Zhang Z, Jian Y, Chen W.
    J Clin Lab Anal; 2024 Sep; 38(17-18):e25072. PubMed ID: 39263925
    [Abstract] [Full Text] [Related]

  • 2. 1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China.
    Li X, Chen W, Wu Y, Li J, Chen L, Fang B, Feng Y, Liu J, Chen M, Gu J, Huang B, Li J.
    Oncologist; 2019 Nov; 24(11):e1132-e1140. PubMed ID: 31455749
    [Abstract] [Full Text] [Related]

  • 3. Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China.
    Gao W, Jian Y, Du J, Li X, Zhou H, Zhang Z, Yang G, Wang G, Tian Y, Li Y, Wu Y, Fu W, Li J, Chen W.
    Cancer Med; 2020 Nov; 9(21):7819-7829. PubMed ID: 32881351
    [Abstract] [Full Text] [Related]

  • 4. Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients.
    Grzasko N, Hus M, Pluta A, Jurczyszyn A, Walter-Croneck A, Morawska M, Chocholska S, Hajek R, Dmoszynska A.
    Hematol Oncol; 2013 Mar; 31(1):41-8. PubMed ID: 22674819
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of daratumumab in newly diagnosed multiple myeloma patients with 1q21 gain.
    Iriuchishima H, Saito A, Mihara M, Terasaki Y, Matsumoto A, Isoda A, Furukawa Y, Matsumoto M.
    Int J Hematol; 2024 Jul; 120(1):71-79. PubMed ID: 38551778
    [Abstract] [Full Text] [Related]

  • 6. Clinical characteristics and prognostic values of 1p32.3 deletion detected through fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma: a single-center study in China.
    Wang H, Meng H, Wang J, Lou Y, Zhou Y, Lin P, Li F, Liu L, Xu H, Yang M, Jin J.
    Front Med; 2020 Jun; 14(3):327-334. PubMed ID: 31784918
    [Abstract] [Full Text] [Related]

  • 7. Complex karyotype determined using conventional cytogenetic analysis is a poor prognostic factor in patients with multiple myeloma.
    Uryu H, Mishima Y, Ishihara Y, Shirouchi Y, Yamauchi N, Hirano M, Hirano K, Teramoto Y, Yoshida K, Maruyama D.
    J Clin Exp Hematop; 2024 Jun; 64(1):10-20. PubMed ID: 38538316
    [Abstract] [Full Text] [Related]

  • 8. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
    Huang WY, Zou DH, Liu W, An G, Xu Y, Sui WW, Deng SH, Li CW, Liu H, Li J, Qiu LG.
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jun 14; 39(6):496-500. PubMed ID: 30032568
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The Importance of FISH Signal Cut-off Value and Copy Number Variation for 1q21 in Newly Diagnosed Multiple Myeloma: Is it Underestimated?
    Gao L, Liu Y, Li Y, Feng L, Wang Z, Wen L, Wang F, Huang X, Lu J, Lai Y.
    Clin Lymphoma Myeloma Leuk; 2022 Jul 14; 22(7):535-544. PubMed ID: 35292207
    [Abstract] [Full Text] [Related]

  • 12. Prognostic value of t(4;14) translocation in newly diagnosed multiple myeloma patients in novel agent era.
    Geng C, Yang G, Zhou H, Wang H, Li Y, Leng Y, Zhang Z, Jian Y, Chen W.
    Hematology; 2023 Dec 14; 28(1):2161222. PubMed ID: 36607148
    [Abstract] [Full Text] [Related]

  • 13. At least two high-risk cytogenetic abnormalities indicate the inferior outcomes for newly diagnosed multiple myeloma patients: a real-world study in China.
    Shen M, Yang G, Li X, Geng C, Huang Z, Chen W.
    Leuk Lymphoma; 2021 Dec 14; 62(12):2992-3001. PubMed ID: 34219587
    [Abstract] [Full Text] [Related]

  • 14. 1q21+ is associated with poor prognosis in newly diagnosed multiple myeloma patients with extramedullary disease: a retrospective study.
    Gao S, Dong F, Yang P, Chen Y, Wang Y, Wang J, Shi Y, Jing H.
    Ann Hematol; 2024 Jun 14; 103(6):1979-1987. PubMed ID: 38206369
    [Abstract] [Full Text] [Related]

  • 15. Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group.
    Grzasko N, Hajek R, Hus M, Chocholska S, Morawska M, Giannopoulos K, Czarnocki K, Druzd-Sitek A, Pienkowska-Grela B, Rygier J, Usnarska-Zubkiewicz L, Dytfeld D, Kubicki T, Jurczyszyn A, Korpysz M, Dmoszynska A.
    Leuk Lymphoma; 2017 Sep 14; 58(9):1-15. PubMed ID: 28092996
    [Abstract] [Full Text] [Related]

  • 16. Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy.
    Nemec P, Zemanova Z, Greslikova H, Michalova K, Filkova H, Tajtlova J, Kralova D, Kupska R, Smetana J, Krejci M, Pour L, Zahradova L, Sandecka V, Adam Z, Buchler T, Spicka I, Gregora E, Kuglik P, Hajek R.
    Biol Blood Marrow Transplant; 2010 Apr 14; 16(4):548-54. PubMed ID: 20005965
    [Abstract] [Full Text] [Related]

  • 17. Prognostic power of abnormal cytogenetics for multiple myeloma: a multicenter study in China.
    Lai YY, Huang XJ, Cai Z, Cao XS, Chen FP, Chen XQ, Chen BA, Fang MY, Feng JF, Fu WL, Guo HY, Hou M, Hou J, Hu Y, Hu XT, Hu XM, Huang LQ, Jin J, Li JY, Li J, Li W, Liang YM, Liu T, Liu QF, Liu YH, Mao P, Ouyang J, Qiu LG, Qiu L, Shao CK, Shi B, Song YP, Sun ZM, Wang QS, Wang C, Wang JM, Wang YS, Wang Z, Wu JB, Wu YX, Xia RX, Xue YQ, Yang BZ, Yang G, Yang ZL, Yu L, Yuan Z, Zhang S, Zhang Y, Zhao HG, Zhao L, Zhou DB, Zou SH, Zhu YF.
    Chin Med J (Engl); 2012 Aug 14; 125(15):2663-70. PubMed ID: 22931972
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Amp 1q21 is more predictable with dismal survival than gain 1q21 of newly diagnosed multiple myeloma in real-world analysis.
    Wang YT, Bao L, Chu B, Chen XH, Lu MQ, Shi L, Gao S, Fang LJ, Xiang QQ, Ding YH.
    J Clin Lab Anal; 2022 Jul 14; 36(7):e24375. PubMed ID: 35353920
    [Abstract] [Full Text] [Related]

  • 20. [The Prognostic Value of Del(1p32) in Patients with Newly Diagnosed Multiple Myeloma].
    Guo R, Shen XX, Xia Y, Jin YY, Li JY, Chen LJ, Qiu HR.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Jun 14; 32(3):768-773. PubMed ID: 38926965
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.